Exclusive Summary

• Breakthrough efficacy delivering functional reversal: In a human IIT, UB433 demonstrated an extraordinary 5.8-point improvement on the ALSFRS-R scale, elevating ALS treatment from merely "delaying decline" to true "functional restoration."
• Gene-independent mechanism unlocking broader markets: Applicable to all ALS subtypes regardless of specific mutations, solving the limited addressable market typical of targeted therapies like Tofersen.
• IV administration with high BBB penetration: Compared to invasive Intrathecal (IT) injections, UB433 is highly effective via standard Intravenous (IV) delivery, dramatically enhancing patient compliance and clinical accessibility.
• Scalable CMC and massive cost advantage: As a cell-free, non-exosomal protein biologic, it leverages a highly standardized manufacturing process that lowers COGS by 60-80% compared to traditional cell therapies.
• Deeply de-risked clinical profile: The asset is backed by robust randomized, double-blind, placebo-controlled human IIT data showing excellent safety and significant reductions in key neurodegenerative biomarkers (e.g., NfL, TDP-43).

Asset Materials

Contact Us for Full Materials